Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.
NTRK inhibitors
PARP inhibitors
immunotherapy
next generation sequencing
ovarian cancer
precision medicine
targeted therapy
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
29 Mar 2022
29 Mar 2022
Historique:
received:
12
01
2022
revised:
16
03
2022
accepted:
25
03
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Ovarian cancer is the deadliest of all gynecologic malignancies claiming the lives of nearly 14,000 women in the United States annually. Despite therapeutic advances, the ovarian cancer mortality rate has remained stagnant since the 1980's. The molecular heterogeneity of ovarian cancers suggest they may be more effectively treated via precision medicine. Current guidelines recommend germline and somatic testing for all new epithelial ovarian cancer diagnoses to assist providers in identifying candidates for targeted therapies. Next generation sequencing (NGS) identifies targetable, driver, and novel mutations used to guide treatment decisions. Performing NGS is standard of care in many other malignancies, but for ovarian cancer the use of NGS in daily practice is still emerging. This review discusses the targetable genetic mutations and role of NGS and molecular biomarker testing in the treatment of ovarian cancer.
Identifiants
pubmed: 35453890
pii: diagnostics12040842
doi: 10.3390/diagnostics12040842
pmc: PMC9030726
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Clin Cancer Res. 2019 Dec 1;25(23):7035-7045
pubmed: 31383735
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
JCO Precis Oncol. 2021 Sep 29;5:
pubmed: 34622117
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Lancet. 2022 Feb 5;399(10324):541-553
pubmed: 35123694
Cells. 2021 Jul 24;10(8):
pubmed: 34440647
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Nat Rev Clin Oncol. 2018 Dec;15(12):731-747
pubmed: 30333516
Am J Surg Pathol. 2012 Feb;36(2):163-72
pubmed: 22189970
Biomedicines. 2021 Jun 18;9(6):
pubmed: 34207450
Cancer Cell Int. 2020 Aug 05;20:373
pubmed: 32774167
Cancer Discov. 2017 Apr;7(4):400-409
pubmed: 28183697
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Gynecol Oncol. 2020 Dec;159(3):887-898
pubmed: 33012552
Gynecol Oncol. 2021 Nov;163(2):312-319
pubmed: 34563366
Int J Cancer. 2011 Oct 15;129(8):1914-22
pubmed: 21140452
J Pathol. 2021 Jan;253(1):41-54
pubmed: 32901952
APMIS. 2021 May;129(5):254-264
pubmed: 33455015
Clin Cancer Res. 2021 Sep 15;27(18):4974-4982
pubmed: 33893159
Gynecol Oncol. 2016 May;141(2):293-302
pubmed: 26972336
Gynecol Oncol. 2014 Feb;132(2):506-12
pubmed: 24333356
Clin Cancer Res. 2008 Nov 1;14(21):6847-54
pubmed: 18980979
Clin Biochem Rev. 2011 Nov;32(4):177-95
pubmed: 22147957
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Ann Oncol. 2020 Nov;31(11):1491-1505
pubmed: 32853681
J Clin Pathol. 2021 Nov;74(11):735-740
pubmed: 33589532
Gynecol Oncol. 2018 Apr;149(1):146-154
pubmed: 29496294
Nature. 2005 Apr 14;434(7035):913-7
pubmed: 15829966
Cancer Res. 2021 Jan 1;81(1):158-173
pubmed: 33158814
Ann Oncol. 2019 Nov 1;30(Suppl_8):viii23-viii30
pubmed: 31738426
Int Immunopharmacol. 2020 Dec;89(Pt A):107126
pubmed: 33189611
Pathol Res Pract. 2019 Oct;215(10):152572
pubmed: 31400924
J Clin Oncol. 2020 Jan 1;38(1):1-10
pubmed: 31682550
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
CA Cancer J Clin. 2011 Jan-Feb;61(1):31-49
pubmed: 21205831
JCO Precis Oncol. 2019 Mar 28;3:
pubmed: 34322651
JCO Precis Oncol. 2018;2018:
pubmed: 30637364
Eur J Cancer. 2016 Jun;60:49-58
pubmed: 27065456
Adv Anat Pathol. 2019 Sep;26(5):329-339
pubmed: 31368906
NPJ Precis Oncol. 2021 Jul 2;5(1):63
pubmed: 34215841
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Front Genet. 2022 Jan 11;12:688207
pubmed: 35087563
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
JCO Oncol Pract. 2020 Aug;16(8):e835-e838
pubmed: 32074015
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Ann Oncol. 2019 Sep 1;30(9):1417-1427
pubmed: 31268127
Am J Surg Pathol. 2020 May;44(5):649-656
pubmed: 32294063
J Natl Compr Canc Netw. 2021 Jul 28;19(7):775-779
pubmed: 34340207
ESMO Open. 2021 Jun;6(3):100144
pubmed: 34015643
J Clin Oncol. 2020 Oct 20;38(30):3468-3493
pubmed: 32790492
Gynecol Oncol. 2019 Jan;152(1):194-201
pubmed: 30297273
Gynecol Oncol. 2020 Dec;159(3):877-886
pubmed: 32967790
JCO Precis Oncol. 2021 Jul 09;5:
pubmed: 34632252
Cancer. 2008 Aug 15;113(4):733-42
pubmed: 18543306
Ann Oncol. 2020 Dec;31(12):1606-1622
pubmed: 33004253
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Gynecol Oncol. 2021 Sep;162(3):686-693
pubmed: 34275654
Discov Med. 2018 Nov;26(144):219-229
pubmed: 30695681
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
ESMO Open. 2019 Nov 25;4(Suppl 2):e000612
pubmed: 31803506
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
J Clin Oncol. 2015 Dec 1;33(34):4015-22
pubmed: 26351349
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254